United States · FDA National Drug Code directory
Lamivudine
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 31722-754_2b44b10b-132c-4593-e063-6294a90a3ffd
- Product NDC
- 31722-754
- Form
- TABLET, FILM COATED
- Composition / generic term
- Lamivudine
- Labeler
- Camber Pharmaceuticals, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20140106
- Source listing expiry
- 20261231
Source-listed ingredients
- LAMIVUDINE — 300 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 600 TABLET, FILM COATED in 1 BOTTLE (31722-754-06) · 31722-754-06
- 30 TABLET, FILM COATED in 1 BOTTLE (31722-754-30) · 31722-754-30
- 10 TABLET, FILM COATED in 1 BLISTER PACK (31722-754-31) · 31722-754-31
- 100 TABLET, FILM COATED in 1 CARTON (31722-754-32) · 31722-754-32
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →